Cargando…
On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906570/ https://www.ncbi.nlm.nih.gov/pubmed/36752889 http://dx.doi.org/10.1007/s10238-023-01010-7 |
| _version_ | 1784884006734528512 |
|---|---|
| author | Boretti, Alberto |
| author_facet | Boretti, Alberto |
| author_sort | Boretti, Alberto |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9906570 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99065702023-02-08 On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia Boretti, Alberto Clin Exp Med Correspondence Springer International Publishing 2023-02-08 /pmc/articles/PMC9906570/ /pubmed/36752889 http://dx.doi.org/10.1007/s10238-023-01010-7 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Boretti, Alberto On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title | On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title_full | On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title_fullStr | On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title_full_unstemmed | On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title_short | On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia |
| title_sort | on the choice of molnupiravir and paxlovid as the only antivirals permitted for covid-19 infection in australia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906570/ https://www.ncbi.nlm.nih.gov/pubmed/36752889 http://dx.doi.org/10.1007/s10238-023-01010-7 |
| work_keys_str_mv | AT borettialberto onthechoiceofmolnupiravirandpaxlovidastheonlyantiviralspermittedforcovid19infectioninaustralia |